U.S. Markets close in 2 hrs 10 mins

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
115.8201-1.2699 (-1.0845%)
As of 1:50PM EDT. Market open.
People also watch
VRTXBMRNALXNREGNSGEN
Full screen
Previous Close117.0900
Open117.6300
Bid115.9300 x 100
Ask116.0000 x 200
Day's Range115.6100 - 118.6100
52 Week Range83.0100 - 153.1500
Volume1,045,459
Avg. Volume1,352,318
Market Cap24.4B
Beta1.63
PE Ratio (TTM)-146.24
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
    Zacks5 days ago

    Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

    Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

  • Reuters6 days ago

    Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis. The finding could be a boost for the drug's prospects, which suffered a setback earlier this year after U.S. regulators turned down an application for its use in rheumatoid arthritis, saying that more data was needed. Baricitinib, in a class of drugs known as Jak inhibitors, is sold in the European Union under the brand name Olumiant for treating rheumatoid arthritis.

  • Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?
    Simply Wall St.6 days ago

    Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?

    Today we’re going to take a look at the well-established Incyte Corporation (NASDAQ:INCY). The company’s stock See our latest analysis for INCY What is INCY worth? INCY appears to beRead More...